Connect with us


Major UK white label CBD plant taken over by Fen Group



A spokesperson for Fen Group said further buyouts are in the pipeline

White Label 360, a CBD manufacturing operation based in the north of England, has been acquired by consumer healthcare firm, Fen Group.

A spokesperson for Fen Group said further buyouts are in the pipeline as they ‘seek to become the dominant player in the UK CBD market’.

Incorporated in 2018, the West Yorkshire-based company will take control of White Label 360’s flagship brand, ‘CBDeaze’.

The company is now awaiting validation from the Food Standards Agency (FSA) as per the new novel foods legislation.

In a statement, Fen Group said the acquisition could open up ‘potential distribution channels’ in Germany and South Africa.

White Label, which has a plant in Barnsley and has been trading since 2015, has 40 white label contacts according to the company’s website.

Its CEO, Colin O’Donnell, said he supported Fen Group’s efforts to ‘bring structure into such a fragmented CBD market in the UK’.

“I am looking forward to working with Fen Group as they endeavour to bring structure into such a fragmented CBD market in the UK,” he commented.

Tom Fennell, CEO of Fen Group said: “This acquisition allows Fen Group to rapidly increase our revenues, whilst keeping our core value proposition consistent.

“We are very excited to build on the foundational work that Colin has put in.”


“TRIP was designed to help people find calm in the chaos”



TRIP co-founders Olivia Ferdi and Daniel Khoury.

Co-founders of the UK-based CBD drinks company TRIP, talk to Cannabis Health about leaving successful careers in law and finance to start their own brand and the impressive rise of the young company since its launch in 2019. 

Olivia Ferdi and Daniel Khoury discovered CBD just a few weeks before their wedding day after Daniel sustained a serious knee injury playing football.

Having torn his anterior cruciate ligament (ACL), Daniel’s doctor told him that he would be unable to walk down the aisle and dancing at the reception would be out of the question.

Meanwhile, Daniel’s brother, who was living in the US at the time, was witnessing the surge in popularity of CBD across North America. He suggested to Daniel that he try the supplement to help reduce the pain and inflammation in his knee.

At this point, CBD was still relatively unknown in the UK and the couple knew nothing about the supplement. But they were willing to try anything to get Daniel back on his feet before their wedding day.

Seven weeks later, Daniel was walking down the aisle without his crutches and “danced all weekend”, Olivia said.

Impressed by the effects of CBD on his recovery, Daniel and Olivia set out to learn more about the supplement. After returning from their wedding abroad, they started researching and discovered the myriad of different health conditions that people were using CBD for.

Olivia then began using CBD to manage her stress and anxiety. Working as a lawyer in London, she found that incorporating CBD into her daily life helped alleviate the stress that came with her job.

“Whether that was taking a few drops on my morning commute or in moments of anxiety to help me reset, CBD quickly became an important part of my routine,” Olivia said.

“We both began using CBD daily after [experiencing] the fantastic everyday benefits for ourselves.”

It wasn’t long before the couple saw an opportunity to bring something different to the market. At the time, CBD hadn’t yet taken off in the UK like it had in the US and the couple struggled to find a product that aligned with their lifestyle and values.

“What was available back then was so inaccessible, whether due to pricing, quality, confusing instructions, off-putting packaging or bitter tastes,” Olivia continued.

“We wanted something convenient and inclusive; a product we could have on our desk at work, grab after a workout or enjoy with friends in the evening.”

The couple took a bold leap, leaving their successful careers in law and finance to launch their very own CBD company, TRIP, with a mission to make CBD more accessible.

TRIP launched a range of high-concentration CBD-infused drinks with flavours and branding that would appeal to young professionals.

Taking a holistic approach to wellness, the drinks contain natural botanical extracts like ginseng, chamomile, Lemon Balm and L-Theanine, which the company says help stabilise physiological processes in the body and alleviate stress.

Since launching at the end of 2019, the company has experienced rapid growth, which Olivia describes as a “whirlwind”. The company got off to an impressive start, working with high-profile brands like Selfridges, Harvey Nichols, Planet Organic and Equinox Gyms.

When the COVID-19 pandemic hit a few months later the company was quick to respond, launching a partnership with Deliveroo to become the first CBD store on the platform.

TRIP went on to be accepted by Sainsbury’s as one of its ‘Future Brands’ and embarked on a partnership with Soho House, the company behind the members-only club that caters to young creatives in major cities across the world.

The brand has also had its share of viral hits on social media with a number of celebrities endorsing the products, including Ellie Goulding who picked up a can of TRIP from her fridge during an interview with Vogue.

“TRIP was designed to help people find calm in the chaos,” Olivia said.

“In 2020 we wanted as many people as possible to experience the amazing benefits of CBD, especially at a time when the need for self-care was at an all-time high. Consumers were reaching for CBD more than ever before, looking for something to ease their worries.

“During this time, we were lucky to experience huge growth and collaborate with some amazing partners in the wellness sector.”

TRIP has already expanded into the European market and plans to announce a number of further global launches in the coming year.

However, despite its big ambitions, Olivia believes it is important not to become “obsessed with lofty goals”. Instead, she says TRIP’s focus on providing the “best experience possible” will lay the groundworks for its future success.

“We are incredibly proud of and thankful for the culture we have cultivated within the TRIP community and we are really excited to keep building our community,” Olivia added.

“We created TRIP so that as many people as possible could experience the benefits of CBD and we plan on continuing in that mission.

Continue Reading


Alphagreen launches crowdfunding drive to grow CBD marketplace



Alphagreen co-founder and CEO Alexej Pikovsky

Online CBD marketplace Alphagreen is launching a crowdfunding campaign as it looks to sustain its growth.

The platform – which claims to be the largest in Europe – allows customers to choose from a range of over 150 lifestyle brands.

Alphagreen co-founder and CEO Alexej Pikovsky

Would-be investors can buy into Alphagreen via equity crowdfunding platform Seedrs, which enables anyone to pursue a stake in a company.

Alphagreen bosses are looking to build on a period which has seen revenue grow from £23,562 in the second quarter of 2020 to £130k in the first quarter of 2021.

Alphagreen co-founder and CEO Alexej Pikovsky co-founder and CEO Alexej Pikovsky, said: “The cannabis industry is here to stay. The global market is poised for a significant growth phase and Alphagreen is perfectly positioned to capitalise on the increased use of medicinal cannabis and fundamental changes to the way the cannabis and CBD market will function.”

Retail investors can register their interest from April 20, 2021. Existing investors include Stockholm-based Enexis AB, US cannabis fund West Creek Investments and angel investors, including Igor and Oleg Tikhturov.

Alphagreen has sets itself an ambitious growth forecast of 300 percent for the remainder of 2021.

The company believes it has benefited from a shift toward online shopping during the Covid-19 pandemic.

Pikovsky added: “We are on track to finish off the year with close to a million pounds in sales and should see a huge jump in 2022 when our content first strategy, together with our e-commerce market place showcasing the very best in health and wellness brand innovation and portfolios, plus massive web traffic that any business would want to be part of really kick in

“We are uniquely positioned and are excited to work with the best brands globally.

Continue Reading


“Positive” Home Office meeting signals change for UK cannabis industry



A meeting took place between key industry stakeholders and Home Office representatives on Wednesday 31 March.

Key stakeholders have indicated a positive step for the UK CBD industry, after meeting with Home Office representatives this week.

In a joint statement the British Hemp Alliance, Cannabis Trades Association, Northern Ireland Hemp Association, Scottish Hemp Association and Unyte Hemp said a “positive meeting” took place with Home Office representatives on Wednesday 31 March.

The urgent meeting was called by the key industry bodies – which collectively represent over 1,000 CBD and hemp businesses in the UK – in a bid to find workable solutions for businesses, regulators and public health officials.

“We would like to thank the Home Office for their swift response to our call for a meeting,” the statement said.

“Speaking on behalf of over 1000 hemp and CBD businesses, the largest and most diverse group in the UK, we discussed the various irregularities facing the hemp industry. 

“These include controlled substances naturally present in trace amounts in hemp foods, import licenses and farming.”

Findings from an upcoming white paper, UK Medicinal Cannabis and CBD market by Professor Mike Barnes and cannabis consultancy firm Maple Tree, were shared in advance of its release, as well as preliminary results from the Great British CBD survey 2021, in which consumers consistently voted in favour of full-spectrum or whole plant products.

In January, the Minister of State for Crime and Policing, Kit Malthouse wrote to the Advisory Council on the Misuse of Drugs (ACMD) calling for further clarity on the legal levels of THC permitted in CBD products. 

Since then the Association for the Cannabinoid Industry (ACI), Centre for Medical Cannabis and the Conservative Drug Policy Reform Group has released a paper recommending a 0.03 percent THC limit should be adopted by the Home Office to address “widespread confusion” over regulations.

Under the proposals, CBD products and hemp strains below those levels would be exempted from controlled status.

In a joint letter last week, the British Hemp Alliance, Cannabis Trades Association, Northern Ireland Hemp Association, Scottish Hemp Association said this would be a “disaster” and is too stringent to allow the UK hemp sector to grow.

Hemp food products have been on the UK market for over 20 years, with trace amounts of controlled substances present.

The Home Office is said to have acknowledged that the 1mg issue was “not relevant to hemp products”, with the exempt definition being intended for research purposes, not for human administration.

They agreed that new regulations would be required to accommodate this growing industry.

The statement continued: “With the requirement of Regulated Product (Novel Food) authorisation, and synthetic cannabinoids entering the food supply for the first time, our proposal for mandatory labelling for classification of contents was well received.

“As part of the Home Office review for changes required to law and regulations, including the Misuse of Drugs Act, will see an immediate improvement to the future of the UK hemp and cannabis industry.

“We will be submitting our evidence to the ACMD.”

A Home Office spokesperson confirmed that they continue to engage with industry stakeholders but its position on CBD and cannabis cultivation remains the same.

While CBD, as an isolated substance, is not a controlled drug, if a product contains THC then it is “highly likely” that the product would be controlled.

They added that those who wish to cultivate cannabis for legitimate purposes must possess the appropriate licence.

A spokesperson said: We have asked the independent Advisory Council on the Misuse of Drugs (ACMD) to provide advice on how we can strengthen and clarify the law on consumer cannabidiol (CBD) products.

“This advice will ensure the law is clear and that these products are safe for consumers, so those who seek to supply legitimate, safe CBD consumer products are able to do so more easily.

“We continue to engage with industry stakeholders but the legislation, our position on CBD and the cultivation of cannabis have not changed.”



Continue Reading